JRCT ID: jRCT2091220388
Registered date:27/09/2018
Basic Information
Recruitment status | PENDING |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 01/10/2018 |
Target sample size | 20 |
Countries of recruitment | Japan,United Kingdom,France,Italy,Austria,South Korea,Denmark,Belgium |
Study type | Interventional |
Intervention(s) | Intervention type:DRUG Name of intervention: Dose form / Japanese Medical Device Nomenclature:TABLET Route of administration / Site of application:ORAL Dose per administration:100~300 mg Dosing frequency / Frequency of use:QD Planned duration of intervention: Intended dose regimen: detailes of teratment arms: Comparative intervention name: Dose form / Japanese Medical Device Nomenclature:INJECTION,INJECTION,INJECTION Route of administration / Site of application:INTRAVENOUS DRIP,INTRAVENOUS DRIP,INTRAVENOUS DRIP Dose per administration:14,1000~1200,120 mg/m^2,mg/m^2,mg/m^2 Dosing frequency / Frequency of use:OTHER, SPECIFY,OTHER, SPECIFY,OTHER, SPECIFY Planned duration of intervention: Intended dose regimen: |
Outcome(s)
Primary Outcome | |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT03593018,JMA-IIA00388 |
Contact
Public contact | |
Name | |
Address | |
Telephone | |
mbjpcti@celgene.com | |
Affiliation | |
Scientific contact | |
Name | |
Address | |
Telephone | |
mbjpcti@celgene.com | |
Affiliation |